Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesions

Martins, A.Oliveira, D. SantosMartins, F. R.Nicolau, R.Pinheiro, F. OliveiraRato, M.Bernardo, A.Pimenta, S.Bernardes, M.Costa, L.2025-03-142025-03-142023-060003-4967http://hdl.handle.net/10400.1/26910European Congress of Rheumatology (EULAR)Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied.engSkinbDMARDAdalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesionsconference object10.1136/annrheumdis-2023-eular.2061